A Study to Investigate ANS03 in Participants With Locally Advanced or Metastatic Solid Tumors

Summary

This is a first-in-human Phase I, multi-center, open-label study of ANS03 in patients with advanced solid tumors. The study evaluates the safety, tolerability, preliminary efficay, pharmacokinetics, anti-tumor activity of ANS03 as monotherapy.

Timeline

Start

2025-03-06

Primary completion

2027-12-30

Completion

2029-03-30

Drugs

Indications